Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 7/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.77 |
| ▸ | FOS | P01100 | 1/20 | 0.70 |
| ▸ | TTR | P02766 | 1/20 | 0.70 |
| ▸ | JUN | P05412 | 1/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.70 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.70 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | LDHA | P00338 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terameprocol SCHEMBL29794162 | 1.00 | ALOX15 (0.77) | ALOX15ALOX12FOSTTRJUN | |
| Terameprocol SCHEMBL10060164 | 1.00 | ALOX15 (0.77) | ALOX15ALOX12FOSTTRJUN | |
| Terameprocol SCHEMBL30094578 | 1.00 | ALOX15 (0.77) | ALOX15ALOX12FOSTTRJUN | |
| Terameprocol SCHEMBL194588 | 1.00 | ALOX15 (0.77) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL4558800 | 0.96 | ALOX15 (0.73) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL15160938 | 0.91 | ALOX15 (0.67) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL14238533 | 0.91 | ALOX15 (0.67) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL14864105 | 0.91 | ALOX15 (0.67) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL16323169 | 0.90 | ALOX15 (0.71) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL2390 | 0.89 | FOS (0.90) | ALOX15ALOX12FOSTTRJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381246-B2 | Cancer therapy | TRIACT THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| US-20150071919-A1 | CANCER THERAPY | TRIACT THERAPEUTICS, INC | 2015-03-12 | — | — | US | claimed |
| US-20140235714-A1 | CANCER THERAPY | TRIACT THERAPEUTICS, INC. (US) | 2014-08-21 | — | — | US | claimed |
| EP-2349235-A1 | USE OF CATECHOLIC BUTANE DERIVATIVES IN CANCER THERAPY | Triact Therapeutics, Inc. (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100256232-A1 | Cancer Therapy | TRIACT THERAPEUTICS, INC. | 2010-10-07 | — | — | US | claimed |
| WO-2010054264-A1 | USE OF CATECHOLIC BUTANE DERIVATIVES IN CANCER THERAPY | TRIACT THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| US-5541232-A | CANCER THERAPY | CHEMEX PHARMACEUTICALS, INC. (US) | 1996-07-30 | — | — | US | claimed |
| WO-1995000129-A1 | TREATMENT OF MULTIDRUG RESISTANT DISEASES | CHEMEX PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | claimed |
| EP-0288534-B1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1991-12-18 | — | — | EP | claimed |
| US-5008294-A | Topical administration | CHEMEX PHARMACEUTICALS, INC. (US) | 1991-04-16 | — | — | US | claimed |
| US-4880637-A | ALCOHOLS, ETHERS OR ESTERS, AS ANTITUMOR AGENTS, SKIN DISORDERS | CHEMEX PHARMACEUTICALS, INC. (US) | 1989-11-14 | — | — | US | claimed |
| EP-0288534-A4 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC. | CHEMEX PHARMACEUTICALS INC (US) | 1989-02-23 | — | — | EP | claimed |
| EP-0297733-A2 | Pharmaceutical compositions comprising catecholic butanes | BLOCK DRUG COMPANY, INC. (US) | 1989-01-04 | — | — | EP | claimed |
| EP-0288534-A1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC. | CHEMEX PHARMACEUTICALS INC (US) | 1988-11-02 | — | — | EP | claimed |
| WO-1988003026-A1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-05-05 | — | — | WO | claimed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| WO-2021108601-A1 | FORMULATIONS OF TERAMEPROCOL AND TEMOZOLOMIDE AND THEIR USE IN STIMULATION OF HUMORAL IMMUNITY IN TUMORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-06-03 | — | — | WO | disclosed |
| EP-0247035-A1 | Optically active dl-nordihydroguaiaretic acid isomers and their racemates, process for preparing them and method of imparting a ple. | CHEMEX PHARMACEUTICALS INC (US) | 1987-12-02 | — | — | EP | disclosed |
| WO-1987002661-A1 | RACEMIC NORDIHYDROGUAIARETIC ACID AND INTERMEDIATES | CHEMEX PHARMACEUTICALS, INC. (US) | 1987-05-07 | — | — | WO | disclosed |
| US-4562298-A | Optically active nordihydroguaiaretic acid and intermediates | CHEMEX PHARMACEUTICALS, INC. (US) | 1985-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235714-A1 | CANCER THERAPY | IGF1R, ERBB2, EGFR | ALOX15 1440/4885ALOX12 1372/4885FOS 2093/4885 |
| US-20100256232-A1 | Cancer Therapy | IGF1R, ERBB2, EGFR | ALOX15 1440/4885ALOX12 1372/4885FOS 2093/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | ALOX15 2988/4885ALOX12 3127/4885FOS 4231/4885 |
| US-20150071919-A1 | CANCER THERAPY | WEE2, WEE1, MAP2K2 | ALOX15 1045/4885ALOX12 959/4885FOS 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.